Ulimorelin Intravenously (IV)
Drug480 microg/kg daily (QD)
NCT Number: NCT01285570
Post-operative administration of ulimorelin is expected to reduce time to recovery of Gastrointestinal (GI) function in patients who have undergone partial large bowel resection.
Looking for future studies?
Notify Me18 year–80 year
All sexes
Interventional
Phase 3
JohnFerenc Del-pesti Hospital, Budapest, Hungary
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
480 microg/kg daily (QD)
Placebo
Time frame: up to 7 days of dosing or until hospital discharge
Time frame: up to 7 days of dosing or hospital discharge
Tranzyme, Inc.
Industry
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Intravenous (IV) Ulimorelin Administered Post-Operatively to Accelerate Recovery of Gastrointestinal (GI) Motility in Subjects Who Have Undergone Partial Bowel Resection
Acronym: ULISES
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT04880538
Gastrointestinal Dysmotility
Baltimore, Maryland, United States
View Trial DetailsNCT01280344
Gastrointestinal Dysmotility
Florence, Alabama, United States
View Trial DetailsNCT01296620
Gastrointestinal Dysmotility
Glendale, California, United States
View Trial Details